⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10707936 | 0.98 | ALDH1A1 (0.53) | — | |
| SCHEMBL7784369 | 0.89 | ALDH1A1 (0.47) | — | |
| Diethylamine SCHEMBL27752034 | 0.84 | ALDH1A1 (0.51) | — | |
| SCHEMBL27623978 | 0.82 | ALDH1A1 (0.57) | — | |
| SCHEMBL38726 | 0.81 | TDP1 (0.61) | — | |
| SCHEMBL11904537 | 0.81 | TDP1 (0.61) | — | |
| SCHEMBL7784366 | 0.80 | PARP10 (0.46) | — | |
| SCHEMBL23727166 | 0.78 | TDP1 (0.58) | — | |
| Bromide SCHEMBL20513084 | 0.78 | TDP1 (0.58) | — | |
| Ammonia Solution, Strong SCHEMBL16240294 | 0.78 | TDP1 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1599 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346568-A1 | PRODUCING 2,5-FURANDICARBOXYLIC ACID IN THE PRESENCE OF MODIFYING ACID | FURANIX TECHNOLOGIES BV (NL) | 2025-11-13 | — | — | US | claimed |
| EP-4540233-A1 | PRODUCING 2,5-FURANDICARBOXYLIC ACID WITH RECOVERY OF ACID | Furanix Technologies B.V. (NL) | 2025-04-23 | — | — | EP | claimed |
| EP-4540236-A1 | PRODUCING 2,5-FURANDICARBOXYLIC ACID FROM MIXED FEED | Furanix Technologies B.V. (NL) | 2025-04-23 | — | — | EP | claimed |
| EP-4540235-A1 | PRODUCING 2,5-FURANDICARBOXYLIC ACID IN THE PRESENCE OF MODIFYING ACID | Furanix Technologies B.V. (NL) | 2025-04-23 | — | — | EP | claimed |
| US-12281090-B2 | Process for producing 2,5-furandicarboxylic acid from ethers of 5-hydroxymethylfurfural | FURANIX TECHNOLOGIES B.V. (NL) | 2025-04-22 | — | — | US | claimed |
| CN-114901648-B | Process for the production of 2, 5-furandicarboxylic acid from ethers of 5-hydroxymethylfurfural | 福兰尼克斯科技公司 | 2025-01-24 | — | — | CN | claimed |
| CN-118930503-A | Purification method and application of 2, 5-furandicarboxylic acid composition | 浙江糖能科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-115626918-B | Phenyl furan-tetrahydroisoquinoline compound and preparation and application thereof | 浙江工业大学 | 2024-11-05 | — | — | CN | claimed |
| CN-118271922-B | High wear-resistant hardening coating liquid composition and production process thereof | 江西昊泽光学膜科技有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-118271922-A | High wear-resistant hardening coating liquid composition and production process thereof | 江西昊泽光学膜科技有限公司 | 2024-07-02 | — | — | CN | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| US-20030225155-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets | POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) | 2003-12-04 | — | — | US | claimed |
| WO-2003084947-A1 | 4,5,6,7-TRETRAHYDROBENZO[B] THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2003-10-16 | — | — | WO | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20030134873-A1 | Adenosine receptor ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-17 | — | — | US | claimed |
| WO-2003031445-A1 | 5-METHOXY-8-ARYL-[1,2,4] TRIAZOLO [1,5-A] PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | claimed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| CN-1350458-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-05-22 | — | — | CN | claimed |